Oxford-based biopharmaceutical company, Adaptimmume Therapeutics plc, has announced the successful manufacturing of the first SPEAR T-cells for a patient at its Philadelphia facility in the USA.
The company, based at Milton Park, is a leader in T-cell therapy to treat cancer. It has also announced an agreement with the UK’s Cell and Gene Therapy Catapult for vector production in the UK. Viral vectors are tools commonly used by molecular biologists to deliver genetic material into cells.
“We are making great strides to becoming a fully integrated cell therapy company,”
said Adaptimmune’s Chief Executive Officer, James Noble. Keith Thompson, CEO, Cell and Gene Therapy Catapult, added:
“This collaboration with Adaptimmune is a great example of a company using the capability we have developed to accelerate GMP (good manufacturing practice) manufacturing for global supply. It is the first announcement of a viral vector manufacturing agreement at the centre and represents part of our commitment to help UK companies overcome barriers to growth.
“Improving the capacity of UK companies and contract manufacturers to supply viral vectors is one of our key priorities, and we are delighted to work with Adaptimmune on this and to support the trials of their SPEAR T-cell therapies.